

CURRICULUM VITAE

KERRI ANN MARIA JOHANNSON
BSc, MD, MPH, FRCPC

I. BIOGRAPHICAL DATA

Kerri A. Johansson	Citizenship: Canadian
South Health Campus	Phone: 403-956-2435
4 th Floor, 4448 Front St. S.E.	Fax: 403-956-2991
Calgary, AB	Email: kerri.johansson2@ucalgary.ca
T3M-1M4 Canada	

Present Rank: Clinical Assistant Professor
Date of Appt: January 15, 2015
Departments: Medicine, joint-appointment in Community Health Sciences
Faculty: Medicine
Institution: University of Calgary

II. ACADEMIC RECORD

i. *Final Degrees:*

2014	Master of Public Health (Environmental Health Sciences), University of California, Berkeley, Berkeley CA, USA
2006	Doctor of Medicine, University of Calgary, Calgary AB, Canada

ii. *Undergraduate:*

1999	Bachelor of Science (Marine Biology), Simon Fraser University, Burnaby BC, Canada
------	--

iii. *Special professional:*

2010, 2012	Fellow of the Royal College of Physicians and Surgeons of Canada
------------	--

iv. *Licensure, Certification and Boards:*

2013	Medical Board of California, specialist license in Pulmonary Medicine
------	--

2012	College of Physicians and Surgeons of Alberta, specialist certification in Internal Medicine and Respiriology
2012	Royal College of Physicians and Surgeons of Canada, specialist certification in Adult Respiriology
2010	Royal College of Physicians and Surgeons of Canada, specialist certification in Internal Medicine
2007	Licentiate of the Medical Council of Canada

III. AWARDS AND DISTINCTIONS

2017	Faculty Honour Roll for Teaching, Course 3, University of Calgary Undergraduate Medical Education, Class of 2018
2012-2014	GSK/University of Calgary Advanced Fellowship in Respiriology (\$35,000/year x 2 years)
2014	Travel Award for Scientific Excellence, 18 th International Colloquium on Lung and Airway Fibrosis, Mont-Tremblant, Quebec (\$1000 CDN)
2013	Walter Travel Grant (\$400 USD towards attendance at American Thoracic Society meeting)
2012	Associate Dean's Letter of Excellence for Teaching, University of Calgary Undergraduate Medical Education, Class of 2014
2007 & 2008	Certificate of Excellence for Clerkship Teaching, University of Calgary Undergraduate Medical Education, Classes of 2007 and 2008
2008	Honourable Mention, Clinical Research Project, Resident Research Day, Faculty of Medicine, University of Calgary
2008	Occupational and Environmental Medical Association of Canada Travel Award to attend OEMAC National Meeting, Quebec City, QC
2003-2006	National Aboriginal Achievement Foundation Medical Student Bursary
2004	Canadian Medical Association Leaders' Forum, Ottawa ON – Student Delegate (\$1500 CDN)
2004	International Elective Award – Alberta Medical Association (\$1000 CDN)
2002	Golden Key International Honour Society Inductee, Simon Fraser University

2001-2002 Dean's List, Faculty of Science, Simon Fraser University

ACADEMIC APPOINTMENTS

2015-Present Clinical Assistant Professor, Department of Community of Health Sciences, University of Calgary

2014-Present Clinical Assistant Professor, Department of Medicine, University of Calgary

2012-2014 Clinical Scholar, Department of Medicine, University of Calgary

2012-2014 Clinical/Research Fellow, Interstitial Lung Disease Program, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco

2012-2014 Health Sciences Clinical Instructor, Department of Medicine, University of California, San Francisco

2009-2012 Bedside Physician, Departments of Medicine (General Internal Medicine & Cardiology) and Critical Care, University of Calgary

2009-2012 Fellow, Division of Respiriology, University of Calgary

2006-2009 Resident Physician, Department of Medicine, University of Calgary

IV. EDUCATIONAL ACTIVITIES

i. Undergraduate

2016-2017 MDCN 370 Respiratory Medicine. Lectures 'Approach to Interstitial Lung Disease', 'Management of Interstitial Lung Disease'

2015 University of Calgary Internal Medicine Academic half-day. 1-hour lecture 'Interstitial Lung Disease for the IM Resident'

2015 MDSC 269: Advanced Topics in Physiology. Two 1.5 hour lectures: 'Environmental Lung Disease', 'Interstitial Lung Disease'

2010-2017 MDCN 370 Respiratory Medicine: Small Group Preceptor

2010-2017 MDCN 370 Respiratory Medicine: Clinical Correlation Preceptor - Bedside Teaching

- 2009-2010 Examiner: Internal Medicine Clerkship OSCE
- 2009 Small Group Preceptor: Introduction to Clerkship Learning Modules

ii. Continuing Education In Medical Teaching

- 2016 Giving Effective Presentations and Feedback, Office of Faculty Development, University of Calgary
- 2015 Leadership Series: Becoming a Talented Mentor, Office of Faculty Development, University of Calgary
- 2011 Pearls for Small Group Teaching, Office of Faculty Development, University of Calgary
- 2010 Tips for Bedside Teaching, Office of Faculty Development, University of Calgary

V. ADMINISTRATIVE RESPONSIBILITIES

i. Faculty:

- 2017 Planning Committee, Division of Respiriology Faculty Retreat
- 2016 - Present Research Sub-Committee, Pulmonary Resident Training Committee, University of Calgary
- 2014 – Present Clinical Academic Rounds Planning Committee, Division of Respiriology, University of Calgary
- 2008-2009 Chief Medicine Resident, Faculty of Medicine, University of Calgary

ii. University:

- 2015 - Present Member, Institute of Public Health, Department of Community Health Sciences, University of Calgary
- 2015 - Present Faculty Mentor, Department of Medicine Resident Mentorship Program, University of Calgary
- 2009-2012 Pulmonary Resident Training Committee, University of Calgary

- | | |
|-------------------------|--|
| 2006-2009 | Internal Medicine Residency Program Committee, University of Calgary |
| 2005-2006 | Student Representative, Internal Medicine Clerkship Committee, University of Calgary |
| 2003-2006 | Student Representative, Federation of Medical Women of Canada, University of Calgary, Medical Class of 2006. |
| <i>iii. Provincial:</i> | |
| 2006-2008 | Council Member, Professional Association of Residents of Alberta |
| <i>iv. National:</i> | |
| 2013-Present | Member, Clinical Assembly for Interstitial Lung Disease, Canadian Thoracic Society |
| 2004-2006 | National Student Representative, Federation of Medical Women of Canada |

VI. PROFESSIONAL ACTIVITIES

i. Membership in professional and learned societies.

Professional Organizations:

Fellow, Royal College of Physicians of Canada

Member, Canadian Medical Association

Member, Alberta Medical Association

Member, American Thoracic Society

Member, Canadian Thoracic Society

Member, European Respiratory Society

Member, The Lung Association, Alberta & NWT

Member, American Thoracic Society Environmental, Occupational and Population Health Assembly

Member, Federation of Medical Women of Canada

ii. *Professional service*

Section Editor

2007-2009 Resident Section, Canadian Journal of General Internal Medicine

Invited Ad-Hoc Reviewer for Peer-Reviewed Journals

Canadian Respiratory Journal (2013-2015), BMC Public Health (2014-2016), Annals of the American Thoracic Society (2015-2017), European Respiratory Journal (2015-2017), PLOS One (2015-2016), American Journal of Respiratory and Critical Care Medicine (2015-2017), Thorax (2016-2017), Journal of Applied Nutrition, Physiology and Metabolism (2016), Respirology (2016-2017).

Invited Moderator

Poster Presentation Sessions American Thoracic Society International Conference (Moderator 2014-2016); Oral Presentation Session American Thoracic Society International Conference (Chair, 2016)

Scientific Symposium Session Proposer and Chair, ATS 2017. Session Title: 'The Gene-Environment Interaction in Interstitial Lung Disease'

Scientific Symposium Session co-Proposer and co-Chair, ATS 2017. Session Title 'Controversies in the Diagnosis of Hypersensitivity Pneumonitis'

Invited Abstract Reviewer

2017 Occupational, Environmental Health Network: American College of Chest Physicians Annual CHEST Meeting, October 2017, Toronto, Ontario

2017 Diffuse Parenchymal Lung Disease: European Respiratory Society Annual Scientific Congress, Sept 2017, Milan Italy

Grant Reviewer

2016 University of Calgary, Dept. of Medicine Research Development Fund

National and International Committees:

2016-Present Planning Committee, American Thoracic Society's Environmental, Occupational and Population Health (EOPH) Assembly

2016-Present Steering Committee, American College of Chest Physicians Occupational and Environmental Health Network

2016-Present	Committee Member, CARE-PF Data Quality and Management
2014-Present	Steering Committee, Canadian Thoracic Society's Clinical Assembly on Pulmonary Fibrosis
2013-2017	Chair, American Thoracic Society Early Career Professionals Working Group; Environmental, Occupational and Population Health (EOPH) Assembly
2013-2017	EOPH Assembly Representative, Early Career Professionals Leadership Working Group, American Thoracic Society
2007-2009	Resident Council Representative, Canadian Society of General Internal Medicine

VII. RESEARCH SUPPORT

Operating Grants: Principal or Co-Investigator:

1. Department of Medicine Research Development Fund, University of Calgary.
Project: Association of Long-Term Air Pollution Exposure with Development and Progression of Idiopathic Pulmonary Fibrosis
Funding period 04/01/2015-03/30/2017 (completed)
Amount: \$10,000 (CDN)
Role: PI
Competitive? Yes
2. CHEST Foundation/Pulmonary Fibrosis Foundation Clinical Research Grant in Pulmonary Fibrosis.
Project: Air Pollution Exposure and Clinical Outcomes in Idiopathic Pulmonary Fibrosis
Funding period 01/11/2013-31/10/2015 (completed)
Amount: \$30,000 (USD)
Role: PI
Competitive? Yes
3. O'Brien Bachelor of Health Sciences Summer Studentship Award
Project: Characterization of the University of Calgary Longitudinal ILD Database
Funding period 01/05/2016-31/08/2016 (completed)
Amount: \$6,000 (CDN)
Student: Chelsea Ford-Sahibzada
Role: Research Supervisor
Competitive? Yes
4. UCB Biotech. Investigator-Initiated Studies Clinical Research Support
Project: Feasibility and Validity of Home Monitoring in Patients with IPF
Funding period 01/04/2017-31/03/2018

Amount: \$135,000 (CDN) (awarded)

Role: PI

Competitive: No

5. University of Calgary Clinical Research Fund
Project: Distance from Subspecialty Clinic, Disease Severity and Clinical Outcomes in Patients with Fibrotic Interstitial Lung Disease
Funding period: 15/06/2017 – 14/06/2018
Amount: \$25,000 (CDN) (awarded)
Role: PI
Competitive? Yes
6. CHEST Foundation Clinical Research Grant in Pulmonary Fibrosis
Project: Social and Environmental Determinants of Mortality in Idiopathic Pulmonary Fibrosis
Funding Period: 1/8/2017 – 31/7/2017
Amount: \$42,000 (USD) (awarded)
Role: PI
Competitive? Yes

VIII. INVITED ADDRESSES

1. *Podcast: Antacid therapy in idiopathic pulmonary fibrosis: More questions than answers?* Lancet Respiratory Medicine. June 23, 2017.
2. *Environmental Health and Interstitial Lung Disease: A Venn Diagram of Opportunity.* O'Brien Institute for Public Health Seminar Series, University of Calgary. Mar 24, 2017.
3. *Interstitial Lung Disease Guideline Update: What's New? What's Changed?* Lung CME 2017, Calgary AB. Feb 11, 2017.
4. *Environmental Risk Factors for Adult Interstitial Lung Disease.* CHEST 2016 Meeting, Los Angeles CA. Oct 25, 2016.
5. *Canadian Thoracic Society Scientific Program: The Diagnostic Evaluation of Fibrotic Interstitial Lung Disease.* CHEST 2016 Meeting, Los Angeles CA. Oct 24, 2016.
6. *Hypersensitivity Pneumonitis in the Agricultural Setting.* CHEST 2016 Meeting, Los Angeles CA. Oct 23, 2016.
7. *The Recommendation for Antacid Therapy in IPF is Generally Sound: Pro Argument.* International School for Interstitial Lung Disease, Erice, Italy. Dec 9, 2015.
8. *New Offenders in Hypersensitivity Pneumonitis.* CHEST 2015 Meeting, Montreal, QC. Oct 25, 2015.

9. *Does this Patient have Hypersensitivity Pneumonitis? Pearls for the Diagnosis of HP.* CHEST 2015 Meeting, Montreal, QC. Oct 25, 2015.
10. *Challenges in Exposure Assessment for Hypersensitivity Pneumonitis.* CHEST 2015 Meeting, Montreal, QC. Oct 27, 2015.
11. *Environmental Exposures and Interstitial Lung Disease.* Pulmonary Fibrosis Patient Support Group, University of Calgary, Calgary AB. June 4, 2015.
12. *Idiopathic Pulmonary Fibrosis: Notes from Underground.* Division of Respiriology Grand Rounds, Royal Columbian Hospital, New Westminster, BC, May 5, 2015.
13. *Three Keys Steps to Grant Success.* Division of Respiriology Resident Research Day, University of Calgary, Ghost River Alberta, Mar 14, 2015.
14. *Pursuing Advanced Fellowship Training.* Division of Respiriology Fellows' Retreat, University of Calgary, Banff Alberta, Jan 9, 2015.
15. *Repeated vs. Intermittent Measures of Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis.* International Colloquium on Airway and Lung Fibrosis, Mont-Tremblant, QC, Canada. Sept 23, 2014.
16. *Air Pollution and Interstitial Lung Disease.* Canadian Respiratory Conference, Calgary Alberta, April 26, 2014.
17. *Air Pollution and Idiopathic Pulmonary Fibrosis.* Pulmonary Grand Rounds, University of California, San Francisco, March 31, 2014.
18. *Interstitial Lung Disease and the Environment.* Patient Support Group, Interstitial Lung Disease Program, University of California, San Francisco, June 11, 2013.
19. *Anatomy and Physiology of the Endocrine System.* Canadian Association of Neurological Nurses Annual Symposium, Calgary AB, Oct 15, 2006.
20. *Dying to be Beautiful: An historical overview of women's morbidity and mortality in the pursuit of physical attractiveness.* Alberta Medical Association's Margaret F. Hutton Lecture Series, Sept 26, 2004.
21. *A Career in Science.* British Columbia Women in Science Organization, Trail BC, Nov 3, 2003.

IX. PUBLICATIONS/PRESENTATIONS

- i. *Peer-Reviewed Articles, Published:*

1. **Johannson KA**, Vittinghoff E, Morisset J, Lee JS, Balmes JR, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. (In Press, European Respiratory Journal)
2. **Johannson KA**, Pendharkar SR, Guenette J, Fell CD, Kalluri M, Mathison K, Kolb M, Ryerson CJ. The Walking Winded: Supplemental Oxygen in Interstitial Lung Disease. *Ann Am Thorac Soc*. 2017 June 23. doi: 10.1513/AnnalsATS.201702-137OI. [Epub ahead of print]
3. **Johannson KA***, Strambu I*, Richeldi L, Wuyts W, Grutters JC, Luppi F, Wells AU, Vancheri C, Kreuters M. Antacid therapy in idiopathic pulmonary fibrosis: More questions than answers. (In Press: *Lancet Respiratory Medicine*) *equal contribution
4. Marcoux V, **Johannson KA**, Fladeland D, Kirby A, Belak ZA. Hot tub lung: A Tale of Two Manifestations. (In Press: *Canadian Journal of Respiratory, Critical Care and Sleep Medicine*)
5. Walsh SL, Hansell D, Flaherty KR, Wilsher M, Nusser R, Poletti V, Martinez FJ, Bendstrup E, Brown KK, Taniguchi H, Crestani B, Cottin V, Vancheri C, Richeldi L, Maher TM, Valeyre D, Nunes H, Kokosi M, Margaritopoulos G, Judge EP, Wijsenbeek M, Grutters JC, Let BJ, Selman M, Morais A, Wuyts WA, Spagnolo P, Glaspole I, Corte TJ, Tomassetti S, Kondoh Y, Kreuter M, Behr J, Kouranos V, Molina-Molina M, **Johannson KA**, Ryerson CJ, Jones M, Wells AU. Diagnostic Accuracy of a Clinical Diagnosis of Idiopathic Pulmonary Fibrosis: An International Case-cohort Study. [In Press: *European Respiratory Journal*]
6. Wang P, Jones KD, Urisman A, Collard HR, **Johannson KA**, Wolters PW, Assayag D, Elicker B, Urbania T, Koth LL. Chronic Hypersensitivity Pneumonitis: Distribution Of pathological patterns in a large prospective cohort. *Chest* 2017 Feb 18 [Epub ahead of print]
7. Brownell R, Henry TS, Elicker BM, Vittinghoff E, Jones KD, Urisman A, Aravena-Leon C, **Johannson KA**, Golden JA, King Jr. TE, Wolters PJ, Collard HR, Ley B. Prediction of histopathologic usual interstitial pneumonia among interstitial lung disease cases with non-definitive computed tomography. *Thorax*. 2017 May;72(5):424-429
8. Morisset J*, **Johannson KA***, Vittinghoff E, Aravena-Leon C, Elicker BM, Jones KD, Fell CD, Manganas H, Dubé B-P, Wolters PJ, Collard HR, Ryerson CJ, Ley B. Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis. *Chest*. 2017 Mar;151(3):619-626. *co-first authors
9. **Johannson KA**. Authors' Response to: Prediction models for hypersensitivity pneumonitis. *Thorax*. 2017 Jan 25.
10. Laratta CL, Tsai WT, Wick J, Pendharkar SE, **Johannson KA**, Ronksley PE. Validity of administrative data for identification of obstructive sleep apnea. *J Sleep Res*. 2017 Apr;26(2):32-138.

11. Laratta CL, **Johannson KA**, Lee AG, Kelly MM, Fell CD. Autoimmune Pulmonary Alveolar Proteinosis with Progressive Fibrosis Refractory to Treatment with Whole lung Lavage, Inhaled Granulocyte Macrophage Colony-Stimulating Factor and Rituximab. *Case Reports in Intern Med* 2017 Feb 2;4(2).
12. **Johannson KA**, Ryerson CJ. What gets measured gets managed: Daily home spirometry in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2016 Oct 15;194(8):926-927.
13. **Johannson KA**, Marcoux VS, Ronksley PE, Ryerson CJ. The Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy in Interstitial Lung Disease: A Systematic Review and Meta-Analysis. *Ann Am Thorac Soc*. 2016 Oct;13(10):1828-1838.
14. Ryerson CJ, Camp PG, Eves ND, Scaeffler M, Syed N, Dhillon S, Jensen D, Maltais F, O'Donnell DE, Raghavan N, Roman M, Stickland ML, Assayag D, Bourbeau J, Dion G, Fell CD, Hambly N, **Johannson KA**, Kalluri M, Khalil N, Kolb M, Managanas H, Moran-Mendoza O, Provencher S, Ramesh W, Rolf JD, Wilcox PG, Guenette JA. High-Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated with Nintedanib: Methodology of the HOPE-IPF Study. *Ann Am Thorac Soc*. 2016 Sept;13(9):1640-7.
15. **Johannson KA**, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Jones KD, King TE Jr, Koth LL, Lee JS, Ley B, Wolters PJ, Collard HR. A diagnostic model for chronic hypersensitivity pneumonitis. *Thorax*. 2016 Oct;71(10):951-4.
16. Ryerson CJ, Tan B, Fell CD, Manganas H, Shapera S, Mittoo S, Sadatsafavi M, To T, Gershon A, Fisher JH, **Johannson KA**, Hambly N, Khalil N, Marras TK, Morisset J, Wilcox PG, Halayko AJ, Khan MA, Kolb M. The Canadian Registry for Pulmonary Fibrosis. *Can Respir J*. 2015 Nov 2. Pii:17206.
17. **Johannson KA**, Ley B, Collard HR. Models of disease behavior in idiopathic pulmonary fibrosis. *BMC Medicine*. 2015 Sept 24;13:165.
18. **Johannson KA**, Balmes JR, Collard HR. Air pollution exposure: A novel risk factor for interstitial lung disease? *Chest*. 2015 Apr 1;147(4):1161-7.
19. **Johannson KA**, Ryerson CJ. Making an accurate diagnosis of chronic hypersensitivity pneumonitis. *Can Respir J*. 2014 November/December;21(6):371-370.
20. **Johannson KA**, de Boer K, Wolters PJ, Golden JA, Lee JS, Collard HR. Correspondence Re: Diagnosis of Idiopathic Pulmonary Fibrosis with high-resolution CT in patients with little or no radiographic evidence of honeycombing: secondary analysis of a randomised clinical trial. *Lancet Resp Med*. 2014 May;2(5):e5.

21. **Johannson KA**, Vittinghoff E, Lee K, Balmes JR, Ji W, Kaplan GG, Kim DS, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. *Eur Respir J*. 2014 Apr;43(4):1124-31.
22. **Johannson KA**, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: A proposal. *Curr Respir Care Rep*. 2013 Dec;2(4).
23. Hasan SA, Eksteen B, Reid D, Paine HV, Alansary A, **Johannson KA**, Gwozd C, Goring KR, Vo T, Proud D, Kelly MM. Role of IL-17A and neutrophils in fibrosis in experimental hypersensitivity pneumonitis. *J Allergy Clin Immunol*. 2013 Jun;131(6) 1663-1673.
24. **Johannson KA**, Huston SM, Mody CH, Davidson W. *Cryptococcus gattii* pneumonia. *Can Med Assoc J* 2012 Sept 4;184(12) 1387-1390.

ii. Abstracts, Published:

1. **Johannson KA**, Vittinghoff E, , Morisset J, Noth E, Balmes JR, Collard HR. Air Pollution Exposure, Lung Function and Dyspnea in Patients with Idiopathic Pulmonary Fibrosis (Accepted for ATS International Conference, May 2017, Washington DC).
2. Barss L, Fraser K, **Johannson KA**. Bronchoalveolar Fluid Cellular Analyses Differ by Laboratory Technique. (Accepted for ATS International Conference, May 2017, Washington DC).
3. Vis DC, Kelly MM, Lee AG, Gelfand G, **Johannson KA**. Contralateral Recurrence of Inflammatory Myofibroblastic Tumour of the Lung Ten Years After Pneumonectomy. (Accepted for ATS International Conference, May 2017, Washington DC).
4. Walsh SL, Hansell D, Flaherty KR, Wilsher M, Nusser R, Poletti V, Martiniez FJ, Bendstrup E, Brown KK, Taniguchi H, Crestani B, Cottin V, Vancheri C, Richeldi L, Maher TM, Valeyre D, Nunes H, Kokosi M, Margaritopoulos G, Judge EP, Wijsenbeek M, Grutters JC, Let BJ, Selman M, Morais A, Wuyts WA, Spagnolo P, Glaspole I, Corte TJ, Tomassetti S, Kondoh Y, Kreuter M, Behr J, Kouranos V, Molina-Molina M, **Johannson KA**, Ryerson CJ, Jones M, Wells AU. Agreement Between Pulmonologists for the Diagnosis of Interstitial Lung Disease: A Study of 275 Pulmonologists from 54 Countries. (Accepted for ATS International Conference, May 2017, Washington DC).
5. Walsh SL, Hansell D, Flaherty KR, Wilsher M, Nusser R, Poletti V, Martiniez FJ, Bendstrup E, Brown KK, Taniguchi H, Crestani B, Cottin V, Vancheri C, Richeldi L, Maher TM, Valeyre D, Nunes H, Kokosi M, Margaritopoulos G, Judge EP, Wijsenbeek M, Grutters JC, Let BJ, Selman M, Morais A, Wuyts WA, Spagnolo P, Glaspole I, Corte TJ, Tomassetti S, Kondoh Y, Kreuter M, Behr J, Kouranos V, Molina-Molina M, **Johannson KA**, Ryerson CJ, Jones M, Wells AU. Accuracy of a Clinical Diagnosis of Idiopathic Pulmonary Fibrosis: A Study of 275 Pulmonologists from 54 Countries. (Accepted for ATS International Conference, May 2017, Washington DC).

6. Ford-Sahibzada CA, Goobie GC, **Johannson KA**, Fell CD. Clinical Characterization of Interstitial Lung Disease Patients: Report from a Single Center Longitudinal Database. (Accepted for ATS International Conference, May 2017, Washington DC).
7. Goobie GC, **Johannson KA**, Ford-Sahibzada CA, Fell CD. Autoantibody Status is Not Associated with Lung Function or Survival in Patients with Idiopathic Pulmonary Fibrosis. (Accepted for ATS International Conference, May 2017, Washington DC).
8. Du Plessis JP, Fernandes S, Jamal R, Camp P, **Johannson KA**, Schaeffer M, Wilcox PG, Guenette JA, Ryerson CJ. Exertional Hypoxemia is More Severe in Fibrotic Interstitial Lung Disease than Chronic Obstructive Pulmonary Disease. (Accepted for ATS International Conference, May 2017, Washington DC).
9. **Johannson KA***, Morrisset J*, Vittinghoff E, Aravena-Leon C, Elicker BM, Jones KD, Fell CD, Manganas H, Dubé B-P, Wolters PJ, Collard HR, Ryerson CJ, Ley B. Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis. (European Respiratory Society Conference 2016, London UK) *co-first authors.
10. Laratta CL, **Johannson KA**, Lee AJ, Kelly MM, Fell CD. Autoimmune Pulmonary Alveolar Proteinosis with Progressive Fibrosis Refractory to Treatment with Whole lung Lavage, Inhaled Granulocyte Macrophage Colony-Stimulating Factor and Rituximab. *Am J Respir Crit Care Med* 193;2016:A5087.
11. **Johannson KA**, Vittinghoff E, Collard HR. A prospective study of weekly home spirometry in patients with Idiopathic Pulmonary Fibrosis. Abstract and poster presentation, ATS International Conference, May 18, 2015. *Am J Respir Crit Care Med* 191;2015:A6367.
12. AlGhamdi A, Daouk S, Collard HR, Lederer DJ, Rosen G, **Johannson KA**, Nathan SD. Impact of Air Pollution on Survival in Patients with Idiopathic Pulmonary Fibrosis. Abstract and poster presentation, ATS International Conference, May 18, 2015. *Am J Respir Crit Care Med* 191;2015:A2512.
13. **Johannson KA**, Elicker B, Vittinghoff E, Jones KD, Lee JS, Wolters PW, Golden J, Koth LL, Collard HR. A clinical model can accurately predict a diagnosis of chronic hypersensitivity pneumonitis. *Am J Respir Crit Care Med* 189;2014:A6583.
14. Wang P, Jones KD, Urisman A, Collard HR, **Johannson KA**, Wolters PW, Assayag D, Elicker B, Urbania T, Koth LL. Chronic Hypersensitivity Pneumonitis: Distribution Of Pathological Patterns In A Large Prospective Cohort. *Am J Respir Crit Care Med* 189;2014:A6402.
15. Dechant A, **Johannson K**. Diffuse alveolar hemorrhage and pneumomediastinum after hypoglycemic seizure. *Eur Respir J* 42;2013:Suppl 57.
16. **Johannson KA**, Vittinghoff E, Lee K, Balmes JR, Ji W, Kaplan GG, Kim DS, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis is associated with increased air pollution exposure. *Am J Respir Crit Care Med* 187;2013:A5981.

17. Hasan S, Gwozd C, Alansary A, Vo T, **Johannson KA**, Eksteen B, Kelly MM. The majority of IL-17A positive cells in hypersensitivity pneumonitis are innate immune cells. *Am J Respir Crit Care Med* 185;2012:A469.
18. Hasan S, Gwozd C, Alansary A, **Johannson KA**, Kelly MM. IL-17A cells in the lung of patients with hypersensitivity pneumonitis. *Can Respir J* 2012;May-Jun 19(3);e47.
19. **Johannson KA**, Huston SM, Mody CH, Davidson W. Unique features of *Cryptococcus gattii* pneumonia – a prolonged incubation period in an immunocompetent host. *Am J Respir Crit Care Med* 183;2011:A5706.
20. Chu A, Vaughn S, **Johannson K**, Viner S, Lord J. Fulminant hepatic failure from Herpes Simplex 1 infection. Canadian Society of General Internal Medicine Scientific Meeting, Montreal QC, Oct 2008.
21. Krongold PH, Myers RP, Dixon E, Hughes R, **Johannson K**, Nash C. Novel ALK-1 mutation in a patient with mesenteric steal syndrome due to hepatic hereditary hemorrhagic telangiectasia. Canadian Digestive Diseases Week, Banff AB, Feb 2006.

iii. *Publications: Manuscripts in Preparation:*

1. **Johannson KA**, Kolb M, Fell CD, Assayag D, Fisher JH, Churg A, de Boer K, Kelly MM, Lee AG, Leipsic J, Manganas H, Mittoo S, Shapera S, Yasufuku K, Ryerson CJ. A Canadian Thoracic Society position paper on the evaluation of fibrotic interstitial lung disease. (Under Revised Review: Canadian Thoracic Society Clinical Guidelines Review Committee)
2. Du Plessis JP, Fernandes S, Jamal R, Camp P, **Johannson KA**, Schaeffer M, Wilcox PG, Guenette JA, Ryerson CJ. Exertional Hypoxemia is More Severe in Fibrotic Interstitial Lung Disease than Chronic Obstructive Pulmonary Disease. (Under Revision: Respiriology)
3. Morisset J, Dubé B-P, de Boer K, Brownell R, **Johannson KA**, Ryerson CJ, Bourbeau J, Collard HR. Development of a questionnaire ASsessing disease Knowledge in patients with Interstitial Lung Disease: The ASK-ILD questionnaire. (Under Review: Annals ATS)

iv. *Non-Peer Reviewed Articles, Published.*

1. **Johannson KA**. Targeting the matrix: Opportunities for therapy. *IPF Expert Exchange* April 2015 (1) 1-2.
2. **Johannson KA**. Challenging cases from the PFF Summit. *IPF Expert Exchange*. April 2015 (1) 3-4.

3. **Johannson KA**, Vipond J, Feroe R. Alberta should seize the opportunity for policy change – coal is the greater danger in our energy rich province. FFwd Weekly, Calgary. June 19, 2013.
4. **Johannson KA**. CaRMS'd again. Can J Gen Int Med 2009;4(3) 194-195.
5. **Johannson KA**. The Boston Experience. Can J Gen Int Med 2008;3(4) 183.
6. **Johannson KA**. The Joy of Sleep. Can J Gen Int Med 2008;3(2) 90.
7. **Johannson KA**. Burma on our Minds. Can J Gen Int Med 2007;2(4) 41.